Iltux HCT is a combination product whose core therapeutic use is in managing symptoms related to systemic imbalance, specifically those associated with high blood pressure (hypertension). The medication is generally applied across domains where additional symptomatic support is needed. The medication serves as a component of symptomatic management.

Managing Symptoms and Enhancing Stability

The medicine is commonly used to help manage conditions characterized by periods of heightened symptoms related to systemic imbalance. It provides support that helps ease the overall symptom burden associated with elevated pressure. It is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed. This medicine is used for managing certain distressing symptoms, conditions associated with acute or disruptive episodes, and scenarios requiring temporary assistance in symptom stabilization.

It provides support that helps ease the overall symptom burden, supporting patients during episodes of heightened discomfort.

Quick Fact Block

Quick Fact: Supports Management of Systemic Imbalance

The medicine is applied across domains where additional symptomatic support is needed, particularly when the condition involves episodic or fluctuating manifestations that may interfere with daily functioning and comfort. It helps address symptom clusters that create noticeable physiological strain, supporting general well-being during symptomatic phases.

Official Eligibility Rules for Iltux HCT

Iltux HCT (Olmesartan Medoxomil/Hydrochlorothiazide) is indicated only for adult patients for the management of hypertension. Official regulatory documents define specific populations who must not use the medicine, as well as groups for whom use is restricted or conditional.

Contraindicated Populations (Must Not Use)

• Pregnant women during the second and third trimesters due to fetal toxicity risk.
• Patients with anuria (inability to produce urine).
• Patients with known hypersensitivity to any component of the medicine or to sulfonamide-derived drugs.
• Patients with severe renal impairment (Creatinine Clearance < 30 mL/min).
• Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
• Patients with Diabetes Mellitus who are concurrently receiving a medicine containing Aliskiren.

Restricted and Conditional Use

• Pediatric Patients: Safety and efficacy have not been established; the medicine is not recommended for this population.
• Lactation: Use is not recommended while breastfeeding.
• Geriatric Patients: Greater caution is advised due to the higher likelihood of age-related declines in organ function.
• Pre-existing Volume/Salt Depletion: This condition must be corrected prior to initiating therapy.
• Patients with Renal Artery Stenosis or Systemic Lupus Erythematosus (SLE) require special consideration and caution.

Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Iltux HCT (Olmesartan Medoxomil and Hydrochlorothiazide) based on pharmacodynamic effects and altered drug exposure.

Official Interaction Statements

• Co-administration with Aliskiren is formally contraindicated in patients with diabetes mellitus or a Glomerular Filtration Rate ( GFR) less than 60 mL/ min/1.73 m^2.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a reduced antihypertensive effect and increased risk of renal function deterioration, especially in the elderly or volume-depleted patients.
• Co-administration with Lithium causes increased serum lithium concentrations and heightened risk of lithium toxicity.
• Potassium-sparing diuretics and potassium supplements increase the risk of hyperkalaemia (elevated serum potassium levels).
• Colesevelam Hydrochloride reduces the systemic exposure of Olmesartan and requires the Iltux HCT dose to be administered at least 4 hours prior to Colesevelam.
• Cholestyramine and Colestipol reduce the absorption of Hydrochlorothiazide and necessitate separation of administration by at least 4 hours before or 4 to 6 hours after the resin.
• Alcohol, barbiturates, or narcotics may intensify the potential for orthostatic hypotension.

Iltux HCT is a combination product that modulates two distinct regulatory pathways. The Iltux component functions as a competitive antagonist at the Angiotensin II type 1 (AT1) receptor, preventing the endogenous vasoconstrictor Angiotensin II from binding. The second component, Hydrochlorothiazide (HCT), acts as a thiazide diuretic. It inhibits the Na^+/Cl^– symporter in the apical membrane of the distal convoluted tubule, preventing the reabsorption of sodium and chloride ions. The combined molecular actions elicit two primary physiological consequences: reduced peripheral vascular resistance due to AT1 receptor blockade, and a decrease in plasma volume secondary to increased renal excretion of sodium and water.

How to Use Iltux HCT: Administration Guidelines

Iltux HCT is a fixed-dose combination medication for hypertension. This medication is not indicated as initial therapy; it is intended for adult patients whose blood pressure is not adequately controlled by either olmesartan or hydrochlorothiazide alone.

Dosage and Schedule

Administration Requirements

The medication may be taken with or without food. The film-coated tablet must be swallowed whole with sufficient fluid, and it should not be chewed. To maintain consistency, it is recommended that the tablet be taken at approximately the same time each day.

Titration and Population Constraints

Dose adjustment (titration) to a higher strength, if necessary, should occur after 2 to 4 weeks of therapy to allow time for the full effect of the current dose to be assessed. Use of Iltux HCT is restricted in patients with severe renal impairment (creatinine clearance <30 mL/min) and is not recommended in the pediatric population as safety and efficacy have not been established.

Research Evidence / Overview of Studies for Iltux HCT

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research for Iltux HCT, a fixed-dose combination, primarily involves randomized controlled trials (RCTs). These are short-term, structured studies that compared the combination against its individual components—Olmesartan or Hydrochlorothiazide—as well as against an inactive placebo (a dummy pill). The combination was studied for adults with essential hypertension (high blood pressure with no known cause), particularly for patients whose pressure was not adequately controlled when taking a single medication alone.

In these trials, researchers primarily monitored the change in seated blood pressure as the main outcome. Studies reported differences in blood pressure change measurements when comparing the combination regimen to the individual components or placebo. Research explored patterns of blood pressure measurement when combining the two agents in a single pill for patients who require more than one medicine.

Study Design and Comparisons

The trials used a double-blind design, meaning neither the patients nor the doctors knew which treatment was being given, and studies monitored the effects of the combination compared to placebo or monotherapy. Factorial design studies were also used; research examined various doses of Olmesartan and Hydrochlorothiazide together to understand how the measured changes evolved across different dosage levels.

Key Measured Outcomes

The main focus of these studies was to monitor physiological strain or stress by measuring blood pressure changes over defined time intervals. These measurements served as a surrogate marker, meaning they are used as a stand-in for a harder, long-term outcome. Regulatory reviews also reference research that monitors the long-term association between blood pressure measurements and cardiovascular events.

Long-Term Research and Durability of Effect

The pivotal trials that established the profile of Iltux HCT were conducted over short-to-intermediate trial durations, typically lasting between 8 and 16 weeks. This research provides insight into short-term changes, but data for long-term effects remain limited.

Evidence regarding the ultimate reduction of major cardiovascular events is often inferred from the short-term blood pressure measurements because direct long-term outcome data are limited. Studies are ongoing to monitor the maintenance and durability of the measured blood pressure changes over longer periods.

Key Studies & References Public Assessment Report for a Medicinal Product for Human Use - Olmesartan/Hydrochlorothiazide STADA Arzneimittel AG (generic regulatory assessment)

Common questions about Iltux HCT (FAQ)

Q: What is the full name of the medication Iltux HCT?

The full pharmaceutical name for the active ingredients in Iltux HCT is Olmesartan Medoxomil and Hydrochlorothiazide. This name reflects the two different medications combined into a single tablet.

Q: What is the difference between Iltux and Iltux HCT?

Iltux HCT is a fixed-dose combination medicine containing two active ingredients. It combines Olmesartan (the single ingredient found in Iltux monotherapy) and Hydrochlorothiazide (HCT), a diuretic. The combination is intended for use in patients who require the action of both components to manage their blood pressure.

Q: Why did my doctor prescribe me Iltux HCT instead of a different blood pressure pill?

Official prescribing information indicates that Iltux HCT is primarily used for adults whose blood pressure is not adequately controlled when taking a single medicine (either olmesartan or hydrochlorothiazide) alone. It combines two different mechanisms of action into one tablet to manage blood pressure, as described in the official indications.

Q: Is Iltux HCT commonly prescribed as a first-line treatment?

No, regulatory documents state that this fixed-dose combination medicine is not indicated for initial therapy (first-line treatment) for high blood pressure. It is intended for patients who need combined pharmacological action to achieve target blood pressure levels.

Q: Is Iltux HCT considered a long-term medication?

Iltux HCT is indicated for the treatment of hypertension (high blood pressure), which is a chronic condition. Management often involves long-term treatment as determined by a healthcare provider.

Q: Why is it important to check blood pressure regularly when taking Iltux HCT?

Lowering high blood pressure is intended to reduce the risk of serious cardiovascular events. Monitoring blood pressure is a standard practice used to observe the medication's effect in maintaining blood pressure within an acceptable range.

Q: How long does it typically take to see the expected effects from Iltux HCT?

The full therapeutic effect of a specific dose is generally assessed after two to four weeks of treatment. This period is allowed for the healthcare provider to fully assess the body's response before any dose adjustments are considered.

Q: What should I know about the olmesartan component in Iltux HCT?

Olmesartan medoxomil is classified as an Angiotensin II Receptor Blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten, and its action is designed to lead to vessel relaxation, which is associated with lowering blood pressure.

Q: What should I know about the hydrochlorothiazide component in Iltux HCT?

Hydrochlorothiazide (HCT) is a thiazide diuretic, a type of water pill. It promotes the kidneys' excretion of excess sodium and water from the body. The result is a decrease in overall blood volume, which helps to manage blood pressure.

Q: What is the active ingredient in Iltux HCT that helps with water retention?

The active ingredient in the combination that assists with the excretion of fluid is Hydrochlorothiazide (HCT). This component acts as a diuretic, helping the kidneys remove excess water and sodium from the body.

Q: How does the HCT part of the name relate to the drug's effect?

The HCT abbreviation stands for Hydrochlorothiazide, which is the diuretic component of the medication. This action supports the overall goal of blood pressure management.

Q: Does Iltux HCT have to be taken at a specific time of day?

The product information states the medication is administered once daily, and consistency in the timing of administration is mentioned. This helps maintain stable levels of the medicine throughout the day.

Q: Does Iltux HCT interact with alcohol?

Yes, official documents state that combining this medicine with alcohol may intensify the potential for orthostatic hypotension. This refers to a sudden drop in blood pressure that can cause dizziness or lightheadedness when standing up quickly.

Q: Are there specific food restrictions listed for Iltux HCT use?

The medication may be taken with or without food. However, consuming potassium-containing salt substitutes or potassium supplements may increase the risk of elevated potassium levels, an interaction that is described in official documents.

Q: Can Iltux HCT cause issues with electrolytes?

Yes, the diuretic component can lead to electrolyte imbalances such as low potassium (hypokalemia) and low sodium (hyponatremia). Official documents describe that regular monitoring of serum electrolytes is generally advised.

Q: Is it normal to feel a bit dizzy when first starting Iltux HCT?

Dizziness is listed in the official documents as a commonly reported adverse reaction. Warnings note that a feeling of light-headedness or dizziness may occur, particularly when first starting therapy or following a dose increase.

Q: Can Iltux HCT cause swelling in the legs or ankles?

Official reports list swelling of the face, hands, feet, or ankles (edema) as a possible adverse reaction associated with the hydrochlorothiazide component. This side effect is described in regulatory documents as a possible adverse reaction.

Q: Are headaches a commonly reported side effect of Iltux HCT?

Headache is not included among the most commonly reported adverse reactions in the official summary. The most common reactions listed include dizziness, nausea, hyperuricemia (increased uric acid), and upper respiratory tract infection.

Q: Is there a risk of skin reactions when using Iltux HCT and being in the sun?

The hydrochlorothiazide component is associated with an increased risk of a serious skin condition called non-melanoma skin cancer. Official warnings mention the need to limit sun exposure due to the medicine’s photosensitizing action.

Q: Are there reasons why someone with kidney problems might not be able to take Iltux HCT?

Yes, the medicine is restricted or not recommended for patients with severe renal impairment (a specific level of reduced kidney function). The drug also has the potential to cause changes in kidney function, which is a factor for healthcare providers to consider.

Q: Is Iltux HCT associated with any long-term health benefits beyond blood pressure control?

Official documents state that the primary long-term benefit of using this drug to lower blood pressure is the reduction of the risk of fatal and nonfatal cardiovascular events. The primary long-term benefit described is the reduction of the risk of fatal and nonfatal cardiovascular events.

Q: Does the efficacy of Iltux HCT change over time?

Clinical studies have monitored the maintenance and durability of the measured blood pressure changes. However, regulatory documents note that data from long-term clinical trials regarding maintained efficacy remain limited, as pivotal studies were typically short to intermediate in duration.

Q: Are there reported differences in how Iltux HCT affects different ethnic groups?

Regulatory documents contain a section on ethnic differences regarding the effect of olmesartan. Any information on potential differences is detailed in the official prescribing information for healthcare providers.

Q: How are the benefits of Iltux HCT generally described in regulatory documents?

Regulatory documents indicate that the medication is intended to treat high blood pressure, and that reducing blood pressure is associated with reducing the risk of fatal and nonfatal cardiovascular events.

Q: Is Iltux HCT approved in other countries besides the US?

Yes, the combination of Olmesartan Medoxomil and Hydrochlorothiazide is approved and regulated by governmental bodies in countries outside of the United States, as indicated by references to European and other global regulatory documents.

Storage Requirements

Iltux HCT tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in the original, tightly closed container to protect it from moisture and excessive heat. Temperature excursions between 15 C and 30 C are permitted for short periods.

Child Safety and Disposal

It is a mandatory requirement to keep Iltux HCT strictly out of the reach and sight of children. Unused or expired medication should be disposed of using a community drug take-back program. If no take-back program is available, the tablets must be mixed with an undesirable substance and placed in a sealed container before discarding in household trash; the medicine must not be flushed down a toilet or sink.